Citation

Wiener CD, Moreira FP, Portela LV, Strogulski NR, Lara DR, da Silva RA, Souza LDM, Jansen K, Oses JP. Psychiatry Res. 2019; 273: 685-689.

Copyright

(Copyright © 2019, Elsevier Publishing)

DOI

10.1016/j.psychres.2019.01.100

PMID

31207853

Abstract

OBJECTIVE: The aim of this study was to assess if cytokines levels (IL-6 and IL-10) are related to major depressive disorder (MDD) and bipolar disorder (BD), in a population-based study.
METHODS: This was a cross-sectional study population-based, involving 1037 people aged 18-35. MDD, BD, anxiety and suicide risk were assessed using the Mini International Neuropsychiatric Interview. Serum IL-6 and IL-10 were measured by ELISA using a commercial kit.
RESULTS: The total sample comprised 1034 young adults, being 14.4% with MDD and 13.7% with BD. MDD and BD groups showed significantly higher serum IL-6 levels (p ≤ 0.001) and IL-10 levels (p ≤ 0.001) when compared to healthy control group. No correlation was found between serum IL-6 and IL-10 levels in health control group (p = 0.830; r = -0.008), non-suicide risk (p = 0.337; r = 0.032) and non-anxiety disorder (p = 0.375; r = 0.031). Covariance analysis showed that mood disorders alone, increase both interleukin levels (IL-6, p = 0.019; and IL-10, p = 0.026), whilst the interaction of mood disorders and suicide risk or anxiety disorders did not.
CONCLUSION: Our results suggest that inflammatory dysregulation may be involved in the physiopathology of mood disorders and serum IL-6 and IL-10 levels are putative biomarkers for these disorders.

Language: en

Keywords

Humans; Cross-Sectional Studies; Adult; Female; Male; Adolescent; Young Adult; Mood Disorders; Psychiatric Status Rating Scales; Biomarkers; Mood disorders; Bipolar Disorder; Depressive Disorder, Major; MDD; IL-6; Interleukin-6; Interleukin-10; BD; IL-10